Durezol and Letairis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Durezol (difluprednate) and Letairis (ambrisentan). Common drug interactions include abdominal distension among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Durezol and Letairis. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Durezol?

Durezol has active ingredients of difluprednate. It is often used in uveitis. eHealthMe is studying from 3,441 Durezol users. Check the latest studies of Durezol.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

On Aug, 11, 2026

13 people who take Durezol and Letairis together, and have interactions are studied.

What are the common drug interactions of Durezol and Letairis, by gender? *:

female:

Abdominal distension
Abdominal pain upper
Chronic kidney disease
Death
Diarrhoea
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Hypocalcaemia (levels of calcium in blood serum are abnormally low)
Nausea (feeling of having an urge to vomit)
Nephrogenic anaemia (anaemia due to kidney disease)

male:

Dyspnoea (difficult or laboured respiration)
Vomiting
Fatigue (feeling of tiredness)
Flushing (the warm, red condition of human skin)
Food allergy
Hypoacusis (loss of hearing)
Malaise (a feeling of general discomfort or uneasiness)
Memory impairment
Nausea (feeling of having an urge to vomit)
Nephrolithiasis (calculi in the kidneys)

What are the common drug interactions of Durezol and Letairis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Infusion site erythema (reddening of the skin at infusion site)
Infusion site hypersensitivity
Infusion site pain

60+:

Dyspnoea (difficult or laboured respiration)
Vomiting
Epistaxis (bleed from the nose)
Fatigue (feeling of tiredness)
Flushing (the warm, red condition of human skin)
Food allergy
Hypoacusis (loss of hearing)
Malaise (a feeling of general discomfort or uneasiness)
Memory impairment
Nausea (feeling of having an urge to vomit)

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 9 people, 69.23%
Oedema (fluid collection in tissue): 1 person, 7.69%
High Blood Cholesterol: 1 person, 7.69%
Gout (uric acid crystals building up in the body): 1 person, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.69%
Fever: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Durezol and Letairis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously